A Patient Guide to Stage 3C Ovarian Cancer: From Neoadjuvant Treatment to Personalized Maintenance

This guide was prepared for patients diagnosed with Stage 3C Ovarian Cancer who are beginning treatment. The treatment pathway includes preoperative chemotherapy and targeted drugs, extensive surgery, and then personalized maintenance treatment (long-term protective treatment).

The aim is to help patients understand their treatment journey, explain in accessible language how the medicines (Paclitaxel, Carboplatin, Bevacizumab, Olaparib, and Niraparib) work, and describe ways to manage side effects.

I. Getting Started: Understanding the Treatment Journey

II. Stage One: Neoadjuvant Treatment (Paclitaxel + Carboplatin + Bevacizumab)

This is the preparatory period planned to reduce tumor burden before surgery and improve the operation's success. Treatment is usually given in 3 to 4 cycles , aiming for maximum effect through the simultaneous use of three different drug classes.

A. Treatment Schedule and Administration Protocol

The neoadjuvant treatment protocol combines two standard chemotherapy drugs (Paclitaxel and Carboplatin) with the targeted treatment Bevacizumab. Administration is usually every 3 or 4 weeks, and all drugs are given intravenously (IV).

This three-drug combination attacks cancer cells from different directions, reducing tumor volume and increasing the likelihood of complete tumor removal (R0 resection) during surgery.

B. How Do the Drugs Work? (Simplified Mechanisms)

1. Carboplatin — Works by Damaging DNA

Carboplatin forms permanent crosslinks between strands of DNA, the cancer cell's genetic material. These links prevent the cell from copying itself and disable its repair mechanism. This drug provides the treatment's “backbone” effect.

2. Paclitaxel — Stops Cell Division

Paclitaxel targets the microtubule structures needed for cell division. By freezingthese structures, it stops cancer cells from multiplying and initiates controlled cell death (apoptosis).

3. Bevacizumab — Shuts Down the Blood Vessels Feeding the Tumor

Cancer needs new blood vessels to grow (angiogenesis). Bevacizumab blocks the protein VEGF , which enables these vessels to form. This cuts off the tumor's oxygen and nutrient supply and enhances the effect of chemotherapy.

C. Common Side Effects of Neoadjuvant Treatment and Their Management

The side effects of chemotherapy and Bevacizumab are usually cyclical and require careful management. The following sections summarize the most common effects and ways to prevent them:

• Low Blood Counts (Myelosuppression): Leukopenia, thrombocytopenia, and anemia may develop. If fever rises above 38°C, seek medical attention immediately.
• Nausea and Vomiting: May begin within 8–12 hours after treatment. Regular antiemetic use is essential.
• Diarrhea: Inform the doctor if diarrhea lasts more than 24 hours or is painful.
• Mouth Sores: Clean teeth with a soft brush 2 times a day.
• Bevacizumab-Related High Blood Pressure: Blood pressure should be measured regularly; blood pressure medication may be added if necessary.

III. Stage Two: Surgery and Recovery (Interval Debulking)

After neoadjuvant chemotherapy reduces tumor burden, the goal is to completely remove all visible cancer tissue in the abdominal cavity (R0 resection). Achieving this goal has been shown to significantly improve long-term survival.

A. Timing and Purpose of Surgery

• Timing: Usually planned after 3–4 cycles of neoadjuvant treatment, following assessment of imaging and clinical response.
• Goal: Achieve maximum tumor cytoreduction (ideally R0); if not possible, minimize residual disease (≤1 cm).
• Next Steps: After recovery, treatment is consolidated with cycles of adjuvant chemotherapy.

B. Scope of Surgery: Which Procedures May Be Considered?

Interval debulking varies from patient to patient but may include some of the following procedures:

• Removal of the uterus and ovaries (TAH+BSO), omentectomy
• Removal of peritoneal implants, diaphragm surface stripping
• Bowel segment resection and anastomosis if needed
• Extended lymph node sampling/selective dissection

C. Bevacizumab Interruption and Wound Healing

• Preoperative interruption: Bevacizumab is withheld for a period before surgery to support wound healing.
• Postoperative restart: Once surgical wounds show adequate healing, the oncology team schedules treatment to restart at an appropriate time.
• Blood pressure control: Managing hypertension before and after surgery is important.

D. Perioperative Preparation and ERAS Principles

ERAS (Enhanced Recovery After Surgery) protocols aim to reduce postoperative pain, complications, and hospital stay.

• Nutrition: Optimize nutrition before surgery; supplements if needed.
• Clot prevention: Compression stockings, prophylactic anticoagulation, and early mobilization.
• Pain management: Multimodal analgesia and approaches that reduce opioid requirements.
• Bowel management: Avoid unnecessary strict fasting and excessive bowel preparation; resume tolerated fluids/solids early.
• Breathing exercises: Spirometer use, coughing, and deep-breathing exercises.

E. Recovery After Surgery and Remaining Treatment

• Recovery time: Usually a few weeks; incision care, temperature monitoring, and mobilization are important.
• Adjuvant chemotherapy: After recovery, usually 3–4 cycles of additional Carboplatin + Paclitaxel are planned.
• Pathology and imaging: The surgical specimen report and postoperative imaging when needed clarify the adjuvant plan.

F. Possible Complications and When to Notify the Team

• High fever (≥38°C), chills
• Severe, persistent abdominal pain or inability to pass gas/vomiting (a sign of ileus)
• Unexpected vaginal/rectal/urinary bleeding
• Redness, discharge, or increasing pain at the incision (wound infection)
• Swelling or pain in the legs, shortness of breath (signs of a clot)

IV. Stage Three: Personalized Maintenance Treatment (A Protective Shield)

After surgery and chemotherapy are complete, the treatment goal becomes preventing the disease from returning. This period is called “maintenance treatment” and is key to long-term survival in ovarian cancer. Treatment is personalized according to HRD test results and the genetic profile.

A. The Role and Importance of Maintenance Treatment

Even if the cancer appears completely removed after surgery, this does not mean it has disappeared at the microscopic level. Maintenance treatmentis given to prevent these invisible cells from multiplying again. The aim is to extend disease-free survival and preserve quality of life.

This treatment is usually a combination of oral PARP inhibitors taken for years or targeted drugs continued intravenously .

B. The HRD (Homologous Recombination Deficiency) Test: A Genetic Compass for Treatment

The HRD testmeasures cancer cells' ability to repair DNA damage. This weakness in DNA repair determines sensitivity to PARP inhibitors.

• HRD-Positive: DNA repair is impaired; the cell is vulnerable. Olaparib + Bevacizumab is the recommended combination.
• HRD-Negative / Uncertain: Repair capacity is partly preserved. Niraparib monotherapy or Bevacizumab maintenance is preferred.

C. PARP Inhibitors: Olaparib and Niraparib (The Mechanism of Synthetic Lethality)

PARP inhibitors target cancer cells by blocking the PARP enzyme , which is involved in DNA repair. In HRD-positive cells, this creates a “double hit”: the cell loses both its own repair mechanism and the PARP pathway and dies. This biological principle is called Synthetic Lethality .

1. Olaparib (in HRD-Positive Patients)

An oral tablet. In HRD-positive patients, it is usually combined with Bevacizumab . Bevacizumab makes tumor tissue hypoxic, enhancing Olaparib's effect; this dual action provides longer recurrence-free survival .

2. Niraparib (Monotherapy)

An oral single-agent treatment. It can be used regardless of HRD results, but is particularly preferred in HRD-negative patients or those for whom Olaparib is unsuitable.

E. Managing Long-Term Side Effects and Quality of Life

• Hematologic Toxicity: Anemia, leukopenia, and thrombocytopenia require regular monitoring. Blood tests should be weekly in the first weeks and monthly thereafter.
• Dose Adjustment: Dose reduction or temporary interruption may be needed based on blood counts.
• Chronic Fatigue: Scheduled rest, balanced nutrition, and light exercise (with the doctor's approval) are recommended.

V. Follow-Up After Treatment and Long-Term Quality of Life

Because the risk of disease returning (recurrence) remains after treatment ends, regular, planned follow-up is very important. This is a critical period not only medically, but also for sustaining physical and psychosocial recovery.

A. The Importance of a Follow-Up Protocol

Follow-up is designed to detect a possible recurrence early . Timely intervention increases the chance of retreatment.

• First 2 years: A check-up every 3–4 months.
• Years 3–5: A check-up every 6–8 months.
• After 5 years: An annual check-up is sufficient.

Each visit includes a gynecologic examination, groin ultrasound, tumor markers (CA-125 , etc.), and imaging such as MRI, CT, or PET-CT when needed.

B. When Should You Call Your Doctor in an Emergency?

Some symptoms after treatment may indicate serious complications. In the following situations, do not wait for the next appointment —contact your doctor immediately:

• Unexpected bleeding from the vagina, rectum, or urinary tract
• High fever (≥38°C) or chills
• Inability to pass gas or severe vomiting (signs of bowel obstruction)
• Persistent, worsening abdominal pain or cramps
• Redness, discharge, or signs of infection at the incision

C. Improving Long-Term Survival and Quality of Life

Life after cancer treatment should be planned not only around “remaining disease-free,” but also around preserving and improving quality of life .

• Physical Activity: Regular walking or light exercise helps combat fatigue.
• Nutrition: Choose a balanced, fiber-rich diet that supports the immune system.
• Psychosocial Support: Cancer treatment is psychologically challenging too. Support groups or professional counseling strengthen recovery.